Abstract: Objective  To systematically evaluate the association between XRCC1 single nucleotide polymorphisms and pancreatic cancer risk. Methods  An electronic search of PubMed， Embase， the Cochrane Library， Web of Science， CBM， Wanfang Data and CNKI  database were conducted. Studies were identified with the criteria for inclusion and exclusion for metaanalysis. Publication bias was examined and sensitivity analysis was also performed. Results  A total of eight  casecontrol  studies were included in the metaanalysis. The combined results showed that there was no significant association between XRCC1 Arg399Gln (rs25487 G>A) mutant and Arg194Trp (rs1799782 C>T)  mutant and pancreatic cancer risk. There was significant association between XRCC1 Arg280His (rs25489 G>A) mutant and pancreatic cancer risk (A vs G: OR=0.743，95%CI=0.5760.958，P=0.022; GA vs GG: OR=0.701，95%CI=0.5250.936，P=0.016; AA+GA vs GG: OR=0.710，95%CI=0.5370.939，P=0.016). Egger linear regression test revealed that there was no publication bias (P＞0.05). Sensitivity analysis showed that the results were robust to the removal of each individual trial from the metaanalysis.Conclusion  This study showed that XRCC1 Arg399Gln (rs25487 G>A)  mutant  and Arg194Trp (rs1799782 C>T)mutant had no significant correlation with the risk of pancreatic cancer. XRCC1 Arg280His (rs25489 G>A) mutant might be associated with the risk of pancreatic cancer.

Key words: pancreatic neoplasms, oncogenes, metaanalysis